Overview
Daniel Aberdam practices in Paris, France. Mr. Aberdam is rated as a Distinguished expert by MediFind in the treatment of EEC Syndrome. His top areas of expertise are Aniridia, EEC Syndrome, Split Hand Foot Malformation, and Aplasia Cutis Congenita.
His clinical research consists of co-authoring 53 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of EEC Syndrome.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- AniridiaMr. Aberdam isElite. Learn about Aniridia.
- Distinguished
- EEC SyndromeMr. Aberdam isDistinguished. Learn about EEC Syndrome.
- Split Hand Foot MalformationMr. Aberdam isDistinguished. Learn about Split Hand Foot Malformation.
- Advanced
- Aplasia Cutis CongenitaMr. Aberdam isAdvanced. Learn about Aplasia Cutis Congenita.
- Clouston SyndromeMr. Aberdam isAdvanced. Learn about Clouston Syndrome.
- Ectodermal DysplasiasMr. Aberdam isAdvanced. Learn about Ectodermal Dysplasias.
- Experienced
- CataractMr. Aberdam isExperienced. Learn about Cataract.
- Hairy Cell Leukemia (HCL)Mr. Aberdam isExperienced. Learn about Hairy Cell Leukemia (HCL).
- Junctional Epidermolysis BullosaMr. Aberdam isExperienced. Learn about Junctional Epidermolysis Bullosa.
- Squamous Cell Skin CarcinomaMr. Aberdam isExperienced. Learn about Squamous Cell Skin Carcinoma.